Published in Bone Marrow Transplant on November 01, 2002
Adverse events among 2408 unrelated donors of peripheral blood stem cells: results of a prospective trial from the National Marrow Donor Program. Blood (2009) 1.96
Lower risk for serious adverse events and no increased risk for cancer after PBSC vs BM donation. Blood (2014) 1.81
Severe events in donors after allogeneic hematopoietic stem cell donation. Haematologica (2008) 1.72
Acute toxicities of unrelated bone marrow versus peripheral blood stem cell donation: results of a prospective trial from the National Marrow Donor Program. Blood (2012) 1.51
G-CSF in Healthy Allogeneic Stem Cell Donors. Transfus Med Hemother (2013) 0.91
Safeguarding the long-term health of hematopoietic stem cell donors: a continuous and evolving process to maintain donor safety and trust. Expert Rev Hematol (2012) 0.80
Bone marrow transplantation after the Chernobyl nuclear accident. N Engl J Med (1989) 3.46
Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol (1998) 3.06
Congestive heart failure in the United States: is there more than meets the I(CD code)? The Corpus Christi Heart Project. Arch Intern Med (2000) 3.03
Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med (2000) 2.78
Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med (2001) 2.66
Beta-lactam antibiotic therapy in febrile granulocytopenic patients. A randomized trial comparing cefoperazone plus piperacillin, ceftazidime plus piperacillin, and imipenem alone. Ann Intern Med (1991) 2.41
Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer. J Clin Oncol (1997) 2.36
T-cell depletion of HLA-identical transplants in leukemia. Blood (1991) 2.25
Community respiratory virus infections among hospitalized adult bone marrow transplant recipients. Clin Infect Dis (1996) 2.12
Allogeneic blood stem cell transplantation: considerations for donors. Blood (1997) 2.03
Treatment of cytomegalovirus retinopathy with ganciclovir. Ophthalmology (1987) 2.03
Chronic myelogenous leukemia: recent advances. Blood (1985) 1.99
Outcome of bone marrow transplantation patients requiring mechanical ventilation. Crit Care Med (2000) 1.85
Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma. J Natl Cancer Inst (2000) 1.81
Should HLA-identical sibling bone marrow transplants for leukemia be restricted to large centers? Blood (1992) 1.77
Impact of high-dose chemotherapy on peripheral T-cell lymphomas. J Clin Oncol (2001) 1.76
Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. Ann Intern Med (1988) 1.73
Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation. Blood (1999) 1.58
Adenovirus infections in adult recipients of blood and marrow transplants. Clin Infect Dis (2001) 1.57
Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant. Bone Marrow Transplant (2004) 1.55
Hepatosplenic gamma-delta T-cell lymphoma: clinicopathological features and treatment. Ann Oncol (2009) 1.52
Low-dose alemtuzumab (Campath) in myeloablative allogeneic stem cell transplantation for CD52-positive malignancies: decreased incidence of acute graft-versus-host-disease with unique pharmacokinetics. Bone Marrow Transplant (2004) 1.50
Accuracy of family history of cancer obtained through interviews with relatives of patients with childhood sarcoma. J Clin Epidemiol (1994) 1.49
Serum cholesterol-lowering activity of granulocyte-macrophage colony-stimulating factor. JAMA (1988) 1.49
Intravenous immune globulin for prevention of cytomegalovirus infection and interstitial pneumonia after bone marrow transplantation. Ann Intern Med (1987) 1.48
High-dose caspofungin combination antifungal therapy in patients with hematologic malignancies and hematopoietic stem cell transplantation. Bone Marrow Transplant (2007) 1.48
The impact of prior invasive mold infections in leukemia patients who undergo allo-SCT in the era of triazole-based secondary prophylaxis. Bone Marrow Transplant (2012) 1.47
Peripheral blood stem cell donation: an analysis from the International Bone Marrow Transplant Registry (IBMTR) and European Group for Blood and Marrow Transplant (EBMT) databases. Bone Marrow Transplant (2001) 1.46
A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia. Cancer Res (1999) 1.45
Bone marrow transplantation for Fanconi anemia. Blood (1995) 1.42
Survival of patients with multiple primary malignancies: a study of 783 patients with gastrointestinal stromal tumor. Ann Oncol (2010) 1.42
Influenza A virus infections among hospitalized adult bone marrow transplant recipients. Bone Marrow Transplant (1994) 1.42
Clinical toxicity and laboratory effects of granulocyte-colony-stimulating factor (filgrastim) mobilization and blood stem cell apheresis from normal donors, and analysis of charges for the procedures. Transfusion (1996) 1.40
Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen. Bone Marrow Transplant (2005) 1.39
Cytomegalovirus infections after allogeneic bone marrow transplantation. Rev Infect Dis (1990) 1.36
Biologic and clinical effects of granulocyte colony-stimulating factor in normal individuals. Blood (1996) 1.33
Combination therapy with aerosolized ribavirin and intravenous immunoglobulin for respiratory syncytial virus disease in adult bone marrow transplant recipients. Bone Marrow Transplant (1995) 1.32
Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trial. Ann Intern Med (1993) 1.31
Common emergence of amantadine- and rimantadine-resistant influenza A viruses in symptomatic immunocompromised adults. Clin Infect Dis (1998) 1.28
Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT. Bone Marrow Transplant (2009) 1.27
Prognostic value of response after upfront therapy for acute GVHD. Bone Marrow Transplant (2011) 1.26
Polymorphisms of DNA repair gene XRCC1 in squamous cell carcinoma of the head and neck. Carcinogenesis (1999) 1.25
XPD/ERCC2 polymorphisms and risk of head and neck cancer: a case-control analysis. Carcinogenesis (2000) 1.25
Genome-wide meta-analyses of smoking behaviors in African Americans. Transl Psychiatry (2012) 1.23
Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies. Bone Marrow Transplant (2006) 1.23
Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease. J Clin Oncol (1996) 1.22
Moxalactam plus piperacillin versus moxalactam plus amikacin in febrile granulocytopenic patients. Am J Med (1984) 1.21
An intronic poly (AT) polymorphism of the DNA repair gene XPC and risk of squamous cell carcinoma of the head and neck: a case-control study. Cancer Res (2001) 1.21
Treatment of AML and MDS relapsing after reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation. Leukemia (2007) 1.20
How does bone-marrow transplantation cure leukaemia? Lancet (1984) 1.19
Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study. Biol Blood Marrow Transplant (2000) 1.17
Efficacy of intensive chemotherapy for acute myelogenous leukemia associated with a preleukemic syndrome. J Clin Oncol (1989) 1.14
Utility of early versus late fiberoptic bronchoscopy in the evaluation of new pulmonary infiltrates following hematopoietic stem cell transplantation. Bone Marrow Transplant (2009) 1.13
B cell reconstitution after human bone marrow transplantation: recapitulation of ontogeny? Bone Marrow Transplant (1993) 1.12
Summary measures of the insulin resistance syndrome are adverse among Mexican-American versus non-Hispanic white children: the Corpus Christi Child Heart Study. Circulation (1997) 1.12
Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after HLA-mismatched marrow or blood stem cell transplantation. Bone Marrow Transplant (1999) 1.11
Implications of potential cure in acute myelogenous leukemia: development of subsequent cancer and return to work. Blood (1997) 1.10
Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia. Blood (1997) 1.09
The hyperactive Sleeping Beauty transposase SB100X improves the genetic modification of T cells to express a chimeric antigen receptor. Gene Ther (2011) 1.09
Factors affecting mobilization of CD34+ cells in normal donors treated with filgrastim. Transfusion (1997) 1.09
Disease burden may identify patients more likely to benefit from second allogeneic hematopoietic stem cell transplantation to treat relapsed acute myelogenous leukemia. Bone Marrow Transplant (2005) 1.07
Allogeneic blood progenitor cell collection in normal donors after mobilization with filgrastim: the M.D. Anderson Cancer Center experience. Transfusion (1999) 1.07
Women and Mexican Americans receive fewer cardiovascular drugs following myocardial infarction than men and non-Hispanic whites: the Corpus Christi Heart Project, 1988-1990. J Clin Epidemiol (1996) 1.07
Bone marrow transplantation for severe aplastic anemia: influence of conditioning and graft-versus-host disease prophylaxis regimens on outcome. Blood (1992) 1.07
Identical-twin bone marrow transplants for leukemia. Ann Intern Med (1994) 1.07
Immunophenotypic and gene expression analysis of monoclonal B-cell lymphocytosis shows biologic characteristics associated with good prognosis CLL. Leukemia (2011) 1.07
Norfloxacin versus vancomycin/polymyxin for prevention of infections in granulocytopenic patients. Am J Med (1986) 1.07
Correlation between selected environmental exposures and karyotype in acute myelocytic leukemia. Cancer Epidemiol Biomarkers Prev (1996) 1.07
Risk factors for the development of invasive fungal infections in allogeneic blood and marrow transplant recipients. Transpl Infect Dis (2002) 1.06
Molecular epidemiology of cytomegalovirus infections associated with bone marrow transplantation. Ann Intern Med (1985) 1.06
Leptin and prostate cancer. Prostate (2001) 1.06
Designed transfer of specific immune responses with bone marrow transplantation. J Clin Invest (1986) 1.05
Long-term results favor allogeneic over autologous hematopoietic stem cell transplantation in patients with refractory or recurrent indolent non-Hodgkin's lymphoma. Ann Oncol (2003) 1.05
Parainfluenza virus infection in adult bone marrow transplant recipients. Eur J Clin Microbiol Infect Dis (1993) 1.04
Cyclin D1 polymorphism and risk for squamous cell carcinoma of the head and neck: a case-control study. Carcinogenesis (2001) 1.04
Allogeneic hematopoietic stem cell transplantation after rituximab-containing myeloablative preparative regimen for acute lymphoblastic leukemia. Bone Marrow Transplant (2006) 1.03
CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood (1995) 1.03
Treatment of donor bone marrow with monoclonal anti-T-cell antibody and complement for the prevention of graft-versus-host disease. A prospective, randomized, double-blind trial. Ann Intern Med (1986) 1.03
CD3(+) and/or CD14(+) depletion from cord blood mononuclear cells before ex vivo expansion culture improves total nucleated cell and CD34(+) cell yields. Bone Marrow Transplant (2009) 1.03
Evaluation of the neurobehavioral functioning of patients before, during, and after bone marrow transplantation. J Clin Oncol (1994) 1.03
Bone marrow transplantation for severe aplastic anemia: has outcome improved? Blood (1997) 1.03
Extracorporeal photopheresis therapy in the management of steroid-refractory or steroid-dependent cutaneous chronic graft-versus-host disease after allogeneic stem cell transplantation: feasibility and results. Bone Marrow Transplant (2003) 1.02
Norfloxacin for prevention of bacterial infections in granulocytopenic patients. Am J Med (1987) 1.01
Treatment of donor graft failure with nonmyeloablative conditioning of fludarabine, antithymocyte globulin and a second allogeneic hematopoietic transplantation. Bone Marrow Transplant (2007) 1.01
Risk factors associated with late cytomegalovirus reactivation after allogeneic stem cell transplantation for hematological malignancies. Bone Marrow Transplant (2007) 1.01
Treatment of acute myelogenous leukemia. A prospective controlled trial of bone marrow transplantation versus consolidation chemotherapy. Ann Intern Med (1985) 1.00
Allogeneic transplantation: a therapeutic option for myelofibrosis, chronic myelomonocytic leukemia and Philadelphia-negative/BCR-ABL-negative chronic myelogenous leukemia. Bone Marrow Transplant (2004) 1.00
Ofloxacin versus vancomycin/polymyxin for prevention of infections in granulocytopenic patients. Am J Med (1990) 1.00
Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effect. Bone Marrow Transplant (1997) 1.00
Chemoprevention of breast cancer with selective estrogen receptor modulators: views from broadly diverse focus groups of women with elevated risk for breast cancer. Psychooncology (2001) 0.99
Is there an increased rate of additional malignancies in patients with mantle cell lymphoma? Ann Oncol (2002) 0.98
Respiratory syncytial virus upper respiratory tract illnesses in adult blood and marrow transplant recipients: combination therapy with aerosolized ribavirin and intravenous immunoglobulin. Bone Marrow Transplant (2000) 0.98
p53 mutations in nonmelanoma skin cancer of the head and neck: molecular evidence for field cancerization. Cancer Res (1995) 0.98
Limiting the location of a putative human prostate cancer tumor suppressor gene at chromosome 13q14.3. Oncogene (1999) 0.98
Bronchoalveolar lavage in the diagnosis of pulmonary complications of bone marrow transplant patients. Bone Marrow Transplant (2000) 0.98
A case-control study of diet and testicular carcinoma. Nutr Cancer (1999) 0.97